Cargando…

Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells

Prostate-specific membrane antigen (PSMA) is an essential molecular regulator of prostate cancer (PCa) progression coded by the FOLH1 gene. The PSMA protein has become an important factor in metastatic PCa diagnosis and radioligand therapy. However, low PSMA expression is suggested to be a resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sommer, Ulrich, Siciliano, Tiziana, Ebersbach, Celina, Beier, Alicia-Marie K., Stope, Matthias B., Jöhrens, Korinna, Baretton, Gustavo B., Borkowetz, Angelika, Thomas, Christian, Erb, Holger H. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835452/ https://www.ncbi.nlm.nih.gov/pubmed/35162969 http://dx.doi.org/10.3390/ijms23031046

Ejemplares similares

Influence of Androgen Deprivation Therapy on the PD-L1 Expression and Immune Activity in Prostate Cancer Tissue
por: Sommer, Ulrich, et al.
Publicado: (2022)

Influence of Systemic Therapy on the Expression and Activity of Selected STAT Proteins in Prostate Cancer Tissue
por: Ebersbach, Celina, et al.
Publicado: (2022)

The Androgen Hormone-Induced Increase in Androgen Receptor Protein Expression Is Caused by the Autoinduction of the Androgen Receptor Translational Activity
por: Siciliano, Tiziana, et al.
Publicado: (2022)

A Systematic Comparison of Antiandrogens Identifies Androgen Receptor Protein Stability as an Indicator for Treatment Response
por: Siciliano, Tiziana, et al.
Publicado: (2021)

Impact of STAT Proteins in Tumor Progress and Therapy Resistance in Advanced and Metastasized Prostate Cancer
por: Ebersbach, Celina, et al.
Publicado: (2021)

Metabolic changes during prostate cancer development and progression
por: Beier, Alicia-Marie K., et al.
Publicado: (2022)

High stroma‐derived WNT5A is an indicator for low‐risk prostate cancer
por: Kisel, Wadim, et al.
Publicado: (2021)

Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?
por: Thomas, Christian, et al.
Publicado: (2021)

Characterization and evaluation of gene fusions as a measure of genetic instability and disease prognosis in prostate cancer
por: Schimmelpfennig, Carolin, et al.
Publicado: (2023)

Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
por: LIU, TIANCHENG, et al.
Publicado: (2012)

Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways
por: Oh, Su Jung, et al.
Publicado: (2012)

Androgens and prostate disease
por: Cooper, Lori A, et al.
Publicado: (2014)

Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
por: Kim, Yejin, et al.
Publicado: (2016)

Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.
por: Theyer, G., et al.
Publicado: (1997)

Expression of androgen receptor and prostate-specific antigen in male breast carcinoma
por: Kidwai, Noman, et al.
Publicado: (2004)

Prostate-Specific Antigen Nadir and Time to Prostate-Specific Antigen Nadir Following Maximal Androgen Blockade Independently Predict Prognosis in Patients with Metastatic Prostate Cancer
por: Hong, Seok Young, et al.
Publicado: (2012)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

HOXB13 is co-localized with androgen receptor to suppress androgen-stimulated prostate-specific antigen expression
por: Kim, Sin Do, et al.
Publicado: (2010)

Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma
por: Chen, Yehui, et al.
Publicado: (2017)

Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression
por: Baretton, G B, et al.
Publicado: (1999)

The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
por: Kiper, Ahmet, et al.
Publicado: (2005)

Prostate-specific antigen dynamics after neoadjuvant androgen-deprivation therapy and carbon ion radiotherapy for prostate cancer
por: Takakusagi, Yosuke, et al.
Publicado: (2020)

Radiotherapy plus androgen deprivation therapy for prostate‐specific antigen persistence in lymph node–positive prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2022)

Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy
por: Teoh, Jeremy YC, et al.
Publicado: (2017)

Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy
por: Meller, B., et al.
Publicado: (2015)

Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation
por: Brady-Nicholls, Renee, et al.
Publicado: (2020)

Androgen resistance in prostate cancer
por: Waxman, J, et al.
Publicado: (2008)

Androgens, aging, and prostate health
por: Welén, Karin, et al.
Publicado: (2022)

The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer
por: Tinhofer, Ingeborg, et al.
Publicado: (2016)

The Challenge to the Pathologist of PD-L1 Expression in Tumor Cells of Non-Small-Cell Lung Cancer—An Overview
por: Jöhrens, Korinna, et al.
Publicado: (2021)

Systems Pharmacology Modeling of Prostate‐Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down‐Regulator
por: Mistry, HB, et al.
Publicado: (2016)

QUANTITATIVE STUDIES OF PROSTATIC SECRETION : III. SIMULTANEOUS MEASUREMENT OF SIZE AND SECRETION OF THE CANINE PROSTATE AND THE INTERACTION OF ANDROGENIC AND ESTROGENIC SUBSTANCES THEREON
por: Huggins, Charles, et al.
Publicado: (1953)

Intraindividual comparison of [(68) Ga]-Ga-PSMA-11 and [(18)F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis
por: Hoberück, Sebastian, et al.
Publicado: (2021)

Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS Lesions
por: Keck, Bastian, et al.
Publicado: (2021)

Identification of androgen-regulated genes in human prostate
por: VAARALA, MARKKU H., et al.
Publicado: (2012)

Retroperitoneal lymph node dissection for testicular cancer is a demanding procedure: detailed real-life data of complications and additional surgical procedures in 295 cases
por: Latarius, Stefanie, et al.
Publicado: (2023)

A prospective study of the effect of testosterone escape on preradiotherapy prostate-specific antigen kinetics in prostate cancer patients undergoing neoadjuvant androgen deprivation therapy
por: Christie, David R.H., et al.
Publicado: (2021)

The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor
por: Aragon-Ching, Jeanny B.
Publicado: (2014)

Regulation of Prostate Androgens by Megalin and 25-hydroxyvitamin D Status: Mechanism for High Prostate Androgens in African American Men
por: Garcia, Jason, et al.
Publicado: (2023)

Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy
por: Lin, Yen-Chi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q2v45rugrl6klgjltsogjnab0g